Committed to developing therapeutics which ablate cancer stem cells for oncology orphan indications.

About Us

Our proprietary compound screening processes accelerate drug discovery development time by utilizing integrative biological and medicinal chemistry approaches. We identify and match drug candidates with disease indications with the goal of reduced clinical and regulatory risks.

Find Out How →

Therapeutic Focus

Our focus is on therapeutics for indications with significant unmet medical need.  Currently, our product development effort is targeting cancer stem cells in acute myelogenous leukemia (AML) and related hematologic malignancies. 

Learn More →